Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The PreHevbrio vaccine produces higher antibody levels and offers faster protection.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
The latest new cancer drugs approved by the Food and Drug Administration
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Robert Califf headed the Food and Drug Administration for 10 months under Obama. Will he manage to implement his ideas this time around?
Scemblix was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
Immunotherapy plus chemotherapy improved overall survival in people with persistent, recurrent or metastatic cervical cancer.
More than half of the therapies in positive industry-sponsored Phase III trials don’t help people with cancer live longer.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
The targeted therapy delayed disease progression or death by approximately nine months.
Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.